Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Search

Astellas Pharma Inc. GLOBAL
  • About
    • Philosophy
      • Charter of Corporate Conduct
    • President and CEO’s Message
    • Vision & Strategy
    • Corporate Governance
      • Group Code of Conduct
    • Corporate Information
      • Subsidiaries & Locations
    • History
    • Board of Directors
    • Top Management
    • Main Products
    • Policies & Position Statements
    • Compliance Initiatives
    • Medical Care & Pharmaceutical Information
    Recommended
    Strategic Plan 2018
    Read More
  • Innovation
    • R&D
      • Approach
      • Ethics & Principles
      • Clinical Trials
      • Pipeline
    • Innovation Hub
    • Partnering
      • Track Record
      • Areas of Interest
      • Register Form
    Recommended
    Clinical Trials

    This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any...

    Read More
  • Responsibility
    • Our Commitment
      • United Global Compact
    • CSR-Based Management
      • Materiality
      • SDGs
      • ISO26000
      • 30% Club
    • Stakeholder Communications
      • Communication with the World Anti-Doping Agency (WADA)
    • CSR Activities in Five Fields
      • Business Activities
        • ISO certification status of Astellas plants
        • With our Business Partners
          • Basic policy for procurement activities involving suppliers
      • Modern Slavery Act 2015
      • Society
        • Advancement of Medical Sciences
        • Changing Tomorrow Day
        • Astellas Foundation
      • Environment
        • Definition of terms
        • EHS Management
          • Status of obtaining ISO 14001 Certification
          • Astellas Environment, Health & Safety Guidelines
        • Environment Initiatives
        • Climate Change Mitigation Measures
        • Breakdown of Energy Consumption
        • Sustainable Biodiversity Initiatives
          • Biodiversity and Astellas An Enlarged Version
          • The Biodiversity Burden Index and Revenue
        • Initiatives for Resource Recycling
        • Initiatives for Preventing Pollution
          • Further information on PRTR system
        • Environmental Impact of Products and Countermeasures
        • Environmental Accounting
          • Environment-related Investments and Expenses
        • Reporting coverage, methods, etc.
        • EHS Report
        • Independent Assurance Report
      • Employees
        • Development and Training
        • Developing Rewarding and Safe Work Environments
        • Human Rights
        • Occupational Health & Safety
        • Data
      • Ethics & Compliance
    • Access to Health
      • Research Activities on Tuberculosis and Malaria
      • Research Activities on NTDs
      • Access Accelerated
      • Action on Fistula
      • Development of Pediatric Formulation for Schistosomiasis
      • GHIT Fund
    • Awards & Recognition
    Recommended
    Access Accelerated

    Astellas participates in Access Accelerated. Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving...

    Read More
  • News
    • News
    • Stories
    Recommended
    Stories

    The “Story” section contains contents focused on “hero”: people (patients, employees, scientists, etc.), scientific innovation and social...

    Read More
  • Investors
    • Strategic Plan 2018
    • Financial Information
      • Financial Highlights
      • Financial Data (Annual Data)
      • Financial Data (Quarterly Data)
      • Sales of Major Products
      • Revenue by Region
    • Annual Report
    • IR Library
      • Business Results
      • Overview of R&D Pipeline
      • IR Meetings
      • Corporate Governance Materials
    • IR Calendar
    • Stock & Rating Information
      • Shareholders Meeting
      • Shareholder Return
      • Current Share Status
      • Chart
      • Issuer Rating
    • Cautionary Statement
    • Analyst Coverage
    Recommended
    Financial Information

    Review our consolidated business results, forecasts and financial data, etc.

    Read More

Common header menu

  • IMPORTANT NOTICE
  • WORLDWIDE
  1. Home
  2. Investors
Important Notice

This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.

Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

I Agree
logo
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Cancel Click here to leave this site.

Investor Relations

Investors
Investors

Stock Quotes(TSE 1st:4503)

View Stock Performance

IR News

Dec 10, 2019
Updated “R&D Meeting” Section
Dec 03, 2019
Posted Presentation Slides for Conference Call :Acquisition of Audentes
Oct 31, 2019
Posted Financial Results for 2Q/FY2019
Oct 01, 2019
Posted Presentation Slides for Conference Call
Jul 30, 2019
Posted Financial Results for 1Q/FY2019
Apr 25, 2019
Posted Financial Results for FY2018
View All >>
Strategic Plan 2018

Our Corporate Strategic Plan 2018 provides a path to realizing VISION in the coming years.

Read More
Financial Information

Review our consolidated business results, forecasts and financial data, etc.

Read More
Annual Report

Annual report site. CEO message, mid- and long-term strategy, corporate governance, business review, and financial information are summarized in this web site.

Read More
IR Library

This section contains IR related information for shareholders and investors. Various IR materials can be downloaded from here.

Read More
IR Calendar

Find our upcoming IR events.

Read More
Stock & Rating Information

Year-end dividend - March 31 Interim dividend - September 30 Note: In accordance with the Company's Articles of Incorporation, if cash dividends are not claimed for three (3) full years from the day of commencement of payment, the Company shall be relieved of the obligation to make such payment.

Read More
Analyst Coverage

List of analysts of securities companies and research companies who make recommendations and reports of Astellas' performance, etc

Read More
Cautionary Statement

The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including shareholders and investors, but is intended to neither solicit nor recommend the purchase of the Astellas's stock.

Read More
Strategic Plan 2018

 

 

Read More
Pipeline

We introduce the progress of our clinical development projects called "R&D pipeline". We update R&D pipeline 4 or 5 times annually in our quarterly performance reports.

Read More
Clinical Trials

This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any products. This site includes information regarding products sold by Astellas in certain countries in the world. However, some of those products are not approved by the regulatory authorities of other countries. For details, please refer to the full Legal Disclaimer.

Read More

Bottom footer menu

  • SITE MAP
  • PRIVACY POLICY
  • ACCESSIBILITY
  • TERMS OF USE
  • CONTACT US
  • DISASTER INFORMATION FOR EMPLOYEES
© Astellas Pharma Inc.